Spyre Therapeutics (SYRE) News Today → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free SYRE Stock Alerts $36.93 +1.74 (+4.94%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSpyre Therapeutics (NASDAQ:SYRE) Shares Gap Up After Analyst Upgradeamericanbankingnews.com - May 11 at 1:38 AMSpyre Therapeutics: Strong Buy Recommendation on Robust Pipeline and Financial Stabilitymarkets.businessinsider.com - May 10 at 7:43 PMBuy Rating Affirmed: Spyre Therapeutics’ Promising Pipeline and Expert Team Drive Positive Outlookmarkets.businessinsider.com - May 10 at 7:43 PMSpyre Therapeutics (NASDAQ:SYRE) Shares Gap Up on Analyst Upgrademarketbeat.com - May 10 at 6:33 PMSpyre Therapeutics (NASDAQ:SYRE) PT Raised to $40.00 at BTIG Researchmarketbeat.com - May 10 at 12:20 PMSpyre Therapeutics, Inc.: Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updatefinanznachrichten.de - May 10 at 8:53 AMSYRE Stock Earnings: Spyre Therapeutics Misses EPS for Q1 2024investorplace.com - May 10 at 12:09 AMSpyre Therapeutics: Q1 Earnings Snapshotchron.com - May 9 at 5:52 PMSpyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updateprnewswire.com - May 9 at 4:02 PMSpyre Therapeutics (NASDAQ:SYRE) Shares Down 5.1% marketbeat.com - May 7 at 6:23 PMSpyre Therapeutics (NASDAQ:SYRE) Now Covered by Analysts at Robert W. Bairdamericanbankingnews.com - May 6 at 6:44 AMSpyre Therapeutics Announces Grants of Inducement Awardsprnewswire.com - May 3 at 5:00 PMBaird Initiates Coverage of Spyre Therapeutics (SYRE) with Outperform Recommendationmsn.com - May 3 at 12:44 PMCarvana upgraded, Block downgraded: Wall Street's top analyst callsmsn.com - May 3 at 2:35 AMSpyre Therapeutics (NASDAQ:SYRE) Now Covered by Robert W. Bairdmarketbeat.com - May 2 at 7:23 AMSpyre Therapeutics (NASDAQ:SYRE) Trading Up 6.1%marketbeat.com - April 29 at 2:32 PMSpyre Therapeutics (NASDAQ:SYRE) Shares Down 5% marketbeat.com - April 24 at 6:15 PMSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by Brokeragesmarketbeat.com - April 23 at 4:11 AMSpyre Therapeutics Inc (SYRE)investing.com - April 20 at 11:52 PMSpyre Therapeutics (SYRE) Price Target Increased by 5.00% to 42.84msn.com - April 17 at 10:38 PMBuy Rating Affirmed for Spyre Therapeutics on Promising mAb Dosing and Market Positioningmarkets.businessinsider.com - April 5 at 3:40 PMSpyre Therapeutics Announces Grants of Inducement Awardsprnewswire.com - April 1 at 5:00 PMSpyre Therapeutics, Inc. (NASDAQ:SYRE) Sees Large Growth in Short Interestmarketbeat.com - March 30 at 12:39 PMSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of "Buy" by Analystsmarketbeat.com - March 29 at 4:11 AMSpyre Therapeutics (NASDAQ:SYRE) Price Target Raised to $54.00marketbeat.com - March 26 at 8:43 AMStrong Buy Rating for Spyre Therapeutics Based on Promising SPY001 Data and Financial Positionmarkets.businessinsider.com - March 25 at 9:15 PMSpyre Therapeutics secures $180 million in PIPE dealinvesting.com - March 20 at 9:17 AMSpyre Therapeutics Privately Places $180 Mln Of Shares; Stock Up In Pre-Marketmarkets.businessinsider.com - March 18 at 10:06 AMSpyre Therapeutics climbs 5%, prices $180M private financingmsn.com - March 18 at 10:06 AMSpyre Therapeutics Announces $180 Million Private Placementprnewswire.com - March 18 at 8:00 AMAnalysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Alnylam Pharma (ALNY) and Spyre Therapeutics (SYRE)markets.businessinsider.com - March 6 at 5:41 PMHere's What Could Help Spyre Therapeutics (SYRE) Maintain Its Recent Price Strengthmsn.com - March 4 at 10:54 AMSpyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awardsfinanznachrichten.de - March 2 at 10:30 AMSpyre Therapeutics Announces Grants of Inducement Awardsprnewswire.com - March 1 at 5:25 PMAnalysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX), Madrigal Pharmaceuticals (MDGL) and Spyre Therapeutics (SYRE)markets.businessinsider.com - March 1 at 1:52 PMBuy Rating for Spyre Therapeutics: Anticipated Clinical Trials and Strategic Advantages Propel Optimismmarkets.businessinsider.com - March 1 at 1:52 PMSpyre Therapeutics (NASDAQ:SYRE) Upgraded at Wells Fargo & Companymarketbeat.com - March 1 at 8:49 AMSpyre Therapeutics, Inc.: Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - March 1 at 7:51 AMTD Cowen Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)markets.businessinsider.com - March 1 at 7:51 AMSpyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updateprnewswire.com - February 29 at 4:05 PMSpyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conferencefinance.yahoo.com - February 26 at 9:34 AMSpyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conferenceprnewswire.com - February 26 at 7:30 AMSpyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisationfinance.yahoo.com - February 8 at 8:46 AMSpyre Therapeutics (NASDAQ:SYRE) Trading Down 6%marketbeat.com - February 8 at 4:24 AMSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by Analystsmarketbeat.com - February 8 at 3:34 AMSpyre Therapeutics Enhances Protection for Executives and Boardmarkets.businessinsider.com - February 6 at 9:44 PMHere's Why Spyre Therapeutics (SYRE) Could be Great Choice for a Bottom Fishermsn.com - February 6 at 3:01 PMSpyre Therapeutics Announces Board Changes and Compensation Updatesmsn.com - February 6 at 10:01 AMSpyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directorsfinance.yahoo.com - February 5 at 8:56 AMSpyre Therapeutics (SYRE) Gets a Buy from Stifel Nicolausmarkets.businessinsider.com - January 16 at 10:03 AM Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address Did You Get Your Free Bitcoin Yet? (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin. >> Register right here SYRE Media Mentions By Week SYRE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SYRE News Sentiment▼0.110.55▲Average Medical News Sentiment SYRE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SYRE Articles This Week▼152▲SYRE Articles Average Week Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PCRX News Today MIRM News Today COLL News Today BLTE News Today PRTA News Today MNKD News Today GYRE News Today IRWD News Today VRNA News Today ABCL News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SYRE) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithCollapse of the Petrodollar Colonial MetalsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
